Status: Recruiting
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
Participants needed: 27
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.Updated: Dec 3, 2025Locations: 2
Eligibility criteria
Able to understand and voluntarily sign an informed consent form. [+6]
Compound small cell lung cancer and transformed small cell lung cancer. [+6]